ADH-1

DB05485InvestigationalProtein Based Therapies

Adherex's biotechnology compound, ADH-1, targets N-cadherin, a protein present on certain tumor cells and established tumor blood vessels. ADH-1 is currently in clinical development in a combination program with a... ADH-1 is currently in clinical development in a combination program with a range of chemotherapeutic agents to investigate the synergistic effects noted in our preclinical models.

Mechanism
Curator reviewed
Primary indication
Investigated for use/treatment in breast cancer, cancer/tumors (unspecified), melanoma, ovarian cancer, and solid tumors.Curator reviewed
Also known as
Cys-His-Ala-Val-Cys
Code names
NSC-729477

Resolves to

Targets

What you can answer from here — as of July 09, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
4Clinical trialsPhase, status and sponsor resolved per trial
Sign in
4+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with ADH-1, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.

Create Account